Literature DB >> 16860657

Cancer vaccines: preclinical studies and novel strategies.

Claudia Palena1, Scott I Abrams, Jeffrey Schlom, James W Hodge.   

Abstract

The development of cancer vaccines, aimed to enhance the immune response against a tumor, is a promising area of research. A better understanding of both the molecular mechanisms that govern the generation of an effective immune response and the biology of a tumor has contributed to substantial progress in the field. Areas of intense investigation in cancer immunotherapy will be discussed here, including: (1) the discovery and characterization of novel tumor antigens to be used as targets for vaccination; (2) the investigation of different vaccine-delivery modalities such as cellular-based vaccines, protein- and peptide-based vaccines, and vector-based vaccines; (3) the characterization of biological adjuvants to further improve the immunogenicity of a vaccine; and (4) the investigation of multimodal therapies where vaccines are being combined with other oncological treatments such as radiation and chemotherapy. A compilation of data from preclinical studies conducted in vitro as well as in animal models is presented here. The results from these studies would certainly support the development of new vaccination strategies toward cancer vaccines with enhanced clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16860657     DOI: 10.1016/S0065-230X(06)95004-0

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  21 in total

1.  Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice.

Authors:  Connie J Rogers; David Berrigan; David A Zaharoff; Kenneth W Hance; Arti C Patel; Susan N Perkins; Jeffrey Schlom; John W Greiner; Stephen D Hursting
Journal:  J Nutr       Date:  2008-01       Impact factor: 4.798

2.  Co-transfection gene delivery of dendritic cells induced effective lymph node targeting and anti-tumor vaccination.

Authors:  Yu-Zhe Chen; Gui-Xin Ruan; Xing-Lei Yao; Li-Ming Li; Ying Hu; Yasuhiko Tabata; Jian-Qing Gao
Journal:  Pharm Res       Date:  2013-02-01       Impact factor: 4.200

Review 3.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

4.  Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens.

Authors:  Adam E Snook; Lan Huang; Stephanie Schulz; Laurence C Eisenlohr; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

Review 5.  Strategies for cancer vaccine development.

Authors:  Matteo Vergati; Chiara Intrivici; Ngar-Yee Huen; Jeffrey Schlom; Kwong Y Tsang
Journal:  J Biomed Biotechnol       Date:  2010-07-11

Review 6.  Therapeutic vaccines for cancer: an overview of clinical trials.

Authors:  Ignacio Melero; Gustav Gaudernack; Winald Gerritsen; Christoph Huber; Giorgio Parmiani; Suzy Scholl; Nicholas Thatcher; John Wagstaff; Christoph Zielinski; Ian Faulkner; Håkan Mellstedt
Journal:  Nat Rev Clin Oncol       Date:  2014-07-08       Impact factor: 66.675

7.  HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Authors:  Liz Y Han; Mavis S Fletcher; Diana L Urbauer; Peter Mueller; Charles N Landen; Aparna A Kamat; Yvonne G Lin; William M Merritt; Whitney A Spannuth; Michael T Deavers; Koen De Geest; David M Gershenson; Susan K Lutgendorf; Soldano Ferrone; Anil K Sood
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

8.  Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo.

Authors:  Nigel G Kooreman; Youngkyun Kim; Patricia E de Almeida; Vittavat Termglinchan; Sebastian Diecke; Ning-Yi Shao; Tzu-Tang Wei; Hyoju Yi; Devaveena Dey; Raman Nelakanti; Thomas P Brouwer; David T Paik; Idit Sagiv-Barfi; Arnold Han; Paul H A Quax; Jaap F Hamming; Ronald Levy; Mark M Davis; Joseph C Wu
Journal:  Cell Stem Cell       Date:  2018-02-15       Impact factor: 24.633

Review 9.  Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.

Authors:  Maria-Cristina S Pranchevicius; Thiessa R Vieira
Journal:  Bioengineered       Date:  2013-04-22       Impact factor: 3.269

Review 10.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.

Authors:  Darryl A Oble; Robert Loewe; Ping Yu; Martin C Mihm
Journal:  Cancer Immun       Date:  2009-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.